TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05756439
Drug: Intravenous Sedatives with or Without Analgesia
Normalized name: E-Z Scrub with Ultradex Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants having dental surgery with conscious intravenous sedation
Study: NCT05756439
Drug: No IV sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants having dental surgery without conscious intravenous sedation
Study: NCT06049108
Drug: [14C]-LY3871801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04966507
Drug: Listerine Antiseptic Mouthwash Product
Normalized name: Listerine Antiseptic Mouthwash Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: COOL MINT LISTERINE® Antiseptic Mouthwash will be used as the 'active' study drug condition. This is a commercially available, over the counter mouthwash product. Active ingredients for this product include Eucalyptol 0.092%, Menthol 0.042%, Methyl salicylate 0.060%, Thymol 0.064%. This product also contains 21% alcohol. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
Study: NCT04966507
Drug: Biotene Mouthwash
Normalized name: BIOTENE MOUTHWASH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biotène Rinse is designed with a moisturizing formula to help relieve dry mouth symptoms and is specifically designed to have a pH similar to saliva. This is a commercially available, over the counter mouthwash product. Biotène Mouthwash Ingredients include: Purified Water, Propylene Glycol, Hydrogenated Starch Hydrolysate, Poloxamer 407, Hydroxyethylcellulose, Sodium Benzoate, Flavor (Peppermint Oil), Benzoic Acid, Disodium Phosphate, Zinc Gluconate, Lactoferrin, Lysozyme, Lactoperoxidase, Potassium Thiocyanate, Aloe Vera Gel, Calcium Lactate, Glucose Oxidase. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
Study: NCT06614985
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An intravenous injection of 0.4 g is administered twice a month.
Study: NCT06614348
Drug: Prednisolone acetate eye drop group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive prednisolone acetate eye drops 4 times per 30min within 2 hours before cataract surgery
Study: NCT04872595
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (60mg/kg/day x 2 days) Day -3 to -2
Study: NCT05593666
Drug: LXE408
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablets
Study: NCT05593666
Drug: AmBisome®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile lyophilised powder in a 15 mL sterile clear glass vial
Study: NCT05604131
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferiprone placebo is the non-medicated formulation for a control arm of the study groups.
Study: NCT05126719
Drug: Capecitabine tablets
Normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered peros
Study: NCT06173570
Drug: AZD0780
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0780 administered orally, once daily for 12 weeks
Study: NCT06173570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally, once daily for 12 weeks
Study: NCT04775225
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: an equivalent amount of saline will be injected subcutaneously in 2 points similar to the active group
Study: NCT04775225
Drug: Steroid
Normalized name: Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 80mg of triamcinolone
Study: NCT05670951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06237400
Drug: ZG19018
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZG19018 Given by PO (mouth)
Study: NCT05285540
Drug: DT-216 matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by intravenous (IV) injection
Study: NCT05722548
Drug: Indomethacin suppository
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg of Indomethacin Suppository sigle dose at the time of induction of anesthesia
Study: NCT05560152
Drug: Yiqihuayu Decotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per os, twice a day, for 7 days.
Study: NCT05702398
Drug: Nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg NAM twice a day for 6 months
Study: NCT05522296
Drug: Mpox Vaccine
Normalized name: smallpox and mpox vaccine, live, nonreplicating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara)
Study: NCT06245109
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg, oral
Study: NCT06245109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, oral
Study: NCT04091022
Drug: Solaraze and Vaniqa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solaraze-topical diclofenac 3% and Vaniqa-topical eflornithine hydrochloride Cream, 13.9% applied to bilateral arms for a period of 9 months
Study: NCT06113055
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT05839756
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml normal saline will be nebulized preoperatively
Study: NCT02133885
Drug: Minocycline Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: These subjects will start with minocycline for 16 weeks, followed by a washout period for 3 weeks, then will receive a placebo for 16 weeks, followed by a washout period for 3 weeks, then will finish with minocycline for 16 weeks.
Study: NCT05212454
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine, 0.5g per pill, given 1250mg/m2 twice a day for 2 weeks of the 3-week treatment course. The total duration of treatment is 8 courses.
Study: NCT06225635
Drug: Ezerosu(monolayer tablet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)
Study: NCT06225635
Drug: Ezerosu(double layer tablet)
Normalized name: aspirin Oral Tablet [Bayer Aspirin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)
Study: NCT05274269
Drug: ELX/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) tablets for oral administration.
Study: NCT05252624
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet manufactured to mimic henagliflozin 5 mg tablet
Study: NCT05793684
Drug: Period B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Week 1: AD816 low dose; Week 2: AD816 high dose
Study: NCT05793684
Drug: Period C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Week 1: Placebo + Placebo; Week 2: Placebo + Placebo
Study: NCT03660917
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug for 6 months, however they will receive riluzole during the last 6 months of study, so that all patients will undergo the active drug in the last phase of the study.
Study: NCT05037851
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care
Study: NCT06508671
Drug: Empty Medication Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take empty medication capsules orally
Study: NCT05989048
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of matching placebo taken within Treatment Phase.
Study: NCT06631300
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo taper will be given to match the same number of pills administered in each stage of the prednisone taper.
Study: NCT05535413
Drug: UTD1 combined with capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: UTD1: 30mg/m2/day, once a day, continuously from day 1 to day 5, 21 days as a treatment cycle.~Capecitabine: 2000mg / m2 / day, continuously from day 1 to day 14, orally twice a day, 21 days as a treatment cycle.
Study: NCT06409195
Drug: SM-020 1% Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to at least 1 and up to 5 Target Lesions (TLs) for 28 days.
Study: NCT06038422
Drug: GTP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refractory/recurrent hemophagocytic lymphohistiocytosis patients will be treated with GTP regimen (Emapalumab+Teniposide+Methylprednisolone)
Study: NCT05838664
Drug: No OAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: AF Patient who were not exposed to oral anticoagulation
Study: NCT04945694
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In this group, patients will receive only incremental doses of intravenous fentanyl
Study: NCT05870670
Drug: NNC0519-0130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously.
Study: NCT05870670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously.
Study: NCT05737784
Drug: PRAX-222 - Initial Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRAX-222
Study: NCT05737784
Drug: PRAX-222 - Initial Ascending Doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending doses of PRAX-222
Study: NCT05225363
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05737784
Drug: PRAX-222 - Optional Ascending Doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalation of PRAX-222 dose(s)
Study: NCT05737784
Drug: PRAX-222 - Fixed Doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose(s) of PRAX-222 not to exceed the maximum tolerated dose of PRAX-222
Study: NCT04968574
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical tablets to the experimental arm with no active ingredient
Study: NCT06629909
Drug: Secretome
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml Injection of secretome for 8 times two weeks apart
Study: NCT05196581
Drug: Dispersible NaCl powder 10 sessions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible NaCl powder 10 sessions
Study: NCT05196581
Drug: Dispersible NaCl powder 5 sessions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible NaCl powder 5 sessions
Study: NCT05480800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 doses of Placebo administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the Placebo_Step 1 and Placebo_Step 2 in Stage 1 (Europe).
Study: NCT06711575
Drug: Anti-Infective Drugs
Normalized name: INVESTIGATIONAL ANTI-INFECTIVE DRUGS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-infective drugs are administered using the traditional clinical dosing regimen, with no interventions.
Study: NCT06710405
Drug: Saline infusion (placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of normal saline in the same volume as that administered to the lidocaine group.
Study: NCT04843761
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
Study: NCT05833438
Drug: VEN+AZA-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 6 cycles: Azacitidine (AZA) 75 mg/m2, d1-5 of each 28 day cycle (SC) in combination with Venetoclax (VEN): 400 mg daily (orally)
Study: NCT04829916
Drug: RMC-035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dosing during 48 hours following cardiac surgery
Study: NCT04829916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dosing during 48 hours following cardiac surgery
Study: NCT06711900
Drug: SKB264
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT05052983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received either 1 (30 mg) or 2 (2\*30 mg) SC injection(s) of placebo every 4 weeks for a period of 24 weeks (with last injection at Week 20). Participants received the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by IRT.
Study: NCT05785429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the intervention group receive one tablet of placebo per day for 12 weeks.
Study: NCT05231460
Drug: Active Comparator: narcotic regimen with TAP block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Narcotic Pain Regimen post-operatively:~* PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~* IV Dilaudid 1mg q3h for breakthrough pain
Study: NCT05231460
Drug: Active Comparator: narcotic regimen with no TAP block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will not receive TAP block and will be administered the following Narcotic Pain Regimen post-operatively:~* PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~* IV Dilaudid 1mg q3h for breakthrough pain
Study: NCT05286567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (blinded)
Study: NCT05594407
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the Remifentanil group, patients will be administered in a total volume of 20 mL, 2 mcg/kg of fentanyl. As maintenance, they will be receiving 1 mL/10kg/h of a remifentanil solution
Study: NCT05144217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule per day of placebo
Study: NCT05144217
Drug: 3x 280 mg per day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsule per day of silimarit
Study: NCT05144217
Drug: 1x 1120 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 capsule per day of silimarit
Study: NCT06421597
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisoline 25 mg/day for seven days
Study: NCT04827719
Drug: BST-236
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recurrent 6 days treatment courses with BST-236 (4.5 g/m2/d administered IV over 1 hour for 6 consecutive days)
Study: NCT06421597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for seven days
Study: NCT05088057
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mg/m² on Day 1 of Cycles 1-4 (Q3W)of the neoadjuvant phase of the study, IV infusion.
Study: NCT05088057
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m² on Day 1 of Cycles 1-4 (Q3W)of the neoadjuvant phase of the study, IV infusion.
Study: NCT06507657
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: intake a placebo oral tablet~At visit 1, after randomization, participants will be provided with bottles containing enough study pills for 3 months duration at 1 tablet daily. Participants will start the study drug on the morning following Visit 1. At the 3 month follow up visit, participants will be provided with enough study pills to complete the remaining 6 months of the study.
Study: NCT06544642
Drug: ASP5502
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT06544642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT05877638
Drug: SILVADENE Cream 1% (silver sulfadiazine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SILVADENE Cream 1% (silver sulfadiazine) is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.
Study: NCT05971537
Drug: antibiotic lock
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the intervention arm, in addition to the appropriate IP antibiotics, an antibiotic-lock will be prepared by the same antibiotics. We will follow the suggested data used in hemodialysis catheter for the concentration of different antibiotics to prepare the locking solution . Some commonly used antibiotics for the treatment of PD peritonitis with their suggested concentrations in the antibiotic-lock are quoted as below:~Cefazolin 10mg/mL Ceftazidime 10mg/mL Vancomycin 10mg/mL Gentamicin 5mg/mL Tienam 50mg/mL
Study: NCT06198894
Drug: Systemic glucocorticoids
Normalized name: Glucocorticoids, Systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups were given oral methylprednisolone (32 mg/d on days 1-5; 16 mg/d on days 6-10; and 8 mg/d on days 11-20),
Study: NCT06198894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups were given systemic glucocorticoid placebo
Study: NCT05187546
Drug: [18F]-PI2620
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 megabecquerel (MBq).
Study: NCT05287724
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken twice daily for seven days
Study: NCT05109078
Drug: [14C]- Rongliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive single dose of orally \[14C\]- Rongliflozin on Day 1
Study: NCT06674525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous injection
Study: NCT05784870
Drug: Shengxuening Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment with Shengxuening Tablets 1 week before chemotherapy, usage: 0.5gtid, for 28 consecutive days
Study: NCT05612594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo once daily
Study: NCT05582317
Drug: Biodentine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricalcium silicate, dicalcium silicate, calcium carbonate and oxide filler, iron oxide shade and zirconium oxide
Study: NCT05582317
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
Study: NCT05630677
Drug: AZD5055 solution for infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single dose intravenous infusion of AZD5055 as 20-minute infusion on Day 1 of the respective period in overnight fasted state.
Study: NCT05630677
Drug: AZD5055 oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive single dose of AZD5055 oral suspension on Day 1 of the respective period in overnight fasted state.
Study: NCT05630677
Drug: AZD5055 film-coated tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in overnight fasted state.
Study: NCT05630677
Drug: AZD5055 film-coated tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in fed state (either a high fat meal or low-fat meal calorie standard breakfast)
Study: NCT05457400
Drug: Glucose Powder
Normalized name: Glucose powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g Glucose Powder dissolved in Water
Study: NCT05767359
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepleting conditioning regimen, nitrogen mustard-derivative, via intravenous infusion per standard care.
Study: NCT04713956
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study: NCT06082856
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction of general anesthesia by administration of sufentanil 0.25µg/Kg (maximum dose 20 µg) intravenously at anesthetic induction.
Study: NCT05671913
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control arm
Study: NCT05946798
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each
Study: NCT05398510
Drug: SHR-2010 injection placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment for intravenously: 2 subjects for placebo. Treatment for subcutaneously: 2 subjects for placebo.
Study: NCT06409637
Drug: FOLFOX4 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX4 regimen: Oxaliplatin 85mg/m2 intravenous infusion over 2 hours on Day 1; Leucovorin 400mg/m2 intravenous infusion over 2 hours on Days 1-2; 5-Fluorouracil (5-FU) initially 400mg/m2 intravenous bolus followed by 2400mg/m2 continuous intravenous infusion over 46 hours. Each cycle lasts for 4 weeks, repeated every 4 weeks for a total of 6-8 cycles.
Study: NCT06047262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive placebo.
Study: NCT04799249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered IV over 30mins prior to chemotherapy on Day 1 and Day 8 of each 21-day cycle.
Study: NCT05036317
Drug: Empagliflozin (Jardiance®;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each tablet contains the active substance of 10 mg empagliflozin as well as the adjuvant lactose-monohydrate and is taken orally once daily in the morning.
Study: NCT04879966
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids was used as induction therapy in UC patients, the maintenance treatment was decided by the researcher
Study: NCT05037032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for naltrexone
Study: NCT05996133
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1 mL epinephrine 1:400,000.
Study: NCT05996133
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL normal saline
Study: NCT00055432
Drug: Gemzar and Alimta
Approvals — FDA: no, EMA: no, PMDA: no